Jasper Therapeutics, Inc.JSPRNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -32.11% |
| Q2 2025 | 31.19% |
| Q1 2025 | -18.28% |
| Q4 2024 | 36.78% |
| Q3 2024 | 27.97% |
| Q2 2024 | 9.69% |
| Q1 2024 | -25.57% |
| Q4 2023 | -6.82% |
| Q3 2023 | 11.66% |
| Q2 2023 | 35.61% |
| Q1 2023 | 5.63% |
| Q4 2022 | 2.88% |
| Q3 2022 | 10.90% |
| Q2 2022 | -0.65% |
| Q1 2022 | -5.42% |
| Q4 2021 | 20.44% |
| Q3 2021 | 39.41% |
| Q2 2021 | 16.65% |
| Q1 2021 | -4.88% |
| Q4 2020 | 2.81% |
| Q3 2020 | -5.36% |
| Q2 2020 | 146.19% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |